Physician profile
Rafael Pajaro
NPI 1700990637
$534.89
in general payments reported to CMS, 2019-2025
13 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $93.39 · 2024: $206 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $153.86 | 2022-2023 | Heplisav-B |
| Pfizer INC. | $96.26 | 2023-2025 | |
| Novo Nordisk INC | $83.58 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $34.70 | 2023-2024 | Shingrix, Arexvy |
| Abbott Laboratories | $29.18 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $22.99 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $19.24 | 2023 | |
| Kyowa Kirin, INC. | $18.96 | 2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $16.19 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $14.68 | 2025 | Breztri |
| Amgen INC. | $14.36 | 2025 | Repatha |
| Lilly USA, LLC | $13.72 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Pajaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.